Answers are grounded in this paper and cite their sources.
Klebsiella pneumoniae (Kp) are encapsulated gram-negative bacteria that cause healthcare-associated and severe community-acquired infections. The global emergence of carbapenem-resistant strains has led the World Health Organization to designate K. pneumoniae a “critical priority” pathogen. This study aimed to identify human monoclonal antibodies (mAbs) with therapeutic potential against multidrug-resistant K. pneumoniae . Using a target-agnostic strategy, we selected human mAbs elicited during an asymptomatic infection with K. pneumoniae . We evaluated the antibody binding to bacterial surface antigens by enzyme-linked immunosorbent assay (ELISA), analytical flow cytometry, and immunoblotting. In vitro , the mAbs were tested by complement-mediated killing and macrophage uptake assays using Kp clinical isolates of differing serotypes. Finally, we evaluated the therapeutic efficacy of the mAbs in a murine pneumonia model with carbapenem-resistant K. pneumoniae . Among the four IgG antibodies identified, mAbKPNA-14 demonstrated specific binding to K. pneumoniae wzi 50:O3b and cross-reactivity with O-antigen type O3/O3a. mAbKPNA-14 significantly enhanced complement-mediated killing ( p < 0.01) and macrophage phagocytosis. In vivo , the therapeutic administration of mAbKPNA-14 reduced bacterial load in the lungs by over 100-fold compared to the control groups ( p < 0.001) and prevented systemic dissemination. This study describes a human mAb that binds to O3b and O3/O3a O-antigens and confers in vivo protection against drug-resistant K. pneumoniae . These findings support the therapeutic potential of mAbs and describe a strategy for isolating and identifying protective mAbs targeting multidrug-resistant bacteria. IMPORTANCE Multidrug-resistant Klebsiella pneumoniae is a critical global health threat for which new therapeutic approaches are urgently needed. Here, we identify a naturally elicited human monoclonal antibody, mAbKPNA-14, which recognizes the O3b O-antigen and cross-reacts with related O3/O3a O-antigens. The antibody promotes complement-mediated killing and macrophage uptake and, when administered therapeutically, reduces pulmonary bacterial burden by more than 100-fold and prevents systemic dissemination in a mouse model of carbapenem-resistant K. pneumoniae pneumonia. These findings demonstrate that protective human antibodies can be isolated directly from individuals following K. pneumoniae infection and identify O-antigen as a promising target for antibody-based therapy. More broadly, our target-agnostic approach provides a strategy for discovering naturally occurring protective antibodies against multidrug-resistant bacterial pathogens.
No takes yet. Share an insight, caveat, or question.
Boniche-Alfaro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: